Epigenetic pathways and glioblastoma treatment.
Epigenetic pathways and glioblastoma treatment.
复制标题
DOI:
10.4161/epi.25440
复制
发表时间:
2013-08
期刊:
影响因子:
3.7
通讯作者:
Ayad NG
中科院分区:
文献类型:
--
作者:
Clarke J;Penas C;Pastori C;Komotar RJ;Bregy A;Shah AH;Wahlestedt C;Ayad NG
Glioblastoma multiforme (GBM) is the most common malignant adult brain tumor. Standard GBM treatment includes maximal safe surgical resection with combination radiotherapy and adjuvant temozolomide (TMZ) chemotherapy. Alarmingly, patient survival at five-years is below 10%. This is in part due to the invasive behavior of the tumor and the resulting inability to resect greater than 98% of some tumors. In fact, recurrence after such treatment may be inevitable, even in cases where gross total resection is achieved. The Cancer Genome Atlas (TCGA) research network performed whole genome sequencing of GBM tumors and found that GBM recurrence is linked to epigenetic mechanisms and pathways. Central to these pathways are epigenetic enzymes, which have recently emerged as possible new drug targets for multiple cancers, including GBM. Here we review GBM treatment, and provide a systems approach to identifying epigenetic drivers of GBM tumor progression based on temporal modeling of putative GBM cells of origin. We also discuss advances in defining epigenetic mechanisms controlling GBM initiation and recurrence and the drug discovery considerations associated with targeting epigenetic enzymes for GBM treatment.
登录
查看更多内容
影响因子:
64.5
作者:
Huarte M;Guttman M;Feldser D;Garber M;Koziol MJ;Kenzelmann-Broz D;Khalil AM;Zuk O;Amit I;Rabani M;Attardi LD;Regev A;Lander ES;Jacks T;Rinn JL
通讯作者:
Rinn JL
DOI:
10.1126/science.1226929
发表时间:
2012-11-23
期刊:
Science (New York, N.Y.)
影响因子:
--
作者:
Friedmann-Morvinski D;Bushong EA;Ke E;Soda Y;Marumoto T;Singer O;Ellisman MH;Verma IM
通讯作者:
Verma IM
影响因子:
3.7
作者:
Hambardzumyan D;Cheng YK;Haeno H;Holland EC;Michor F
通讯作者:
Michor F
影响因子:
64.5
作者:
Hah N;Danko CG;Core L;Waterfall JJ;Siepel A;Lis JT;Kraus WL
通讯作者:
Kraus WL
影响因子:
15.8
作者:
Ioannidis, JPA
通讯作者:
Ioannidis, JPA